OCC Applauds FDA for Approval of New Obesity Drug
This Post has No Comments
Today, members of the Obesity Care Continuum (OCC) applauded the Food and Drug Administration’s (FDA) approval of a new obesity drug – Belviq (lorcaserin HCl). Belviq is the first obesity drug to be approved in the past 13 years.
To view the full release, click here.